Safety for Home Administration of Microdose Psilocybin Use

Randomised, sequential laboratory study in healthy volunteers (n=20) testing ascending microdoses of psilocybin trihydrate (1.2, 2.0, 3.0, 4.2 mg) with a single interspersed randomized placebo session to identify the highest safe at-home dose.

Five double-blind laboratory dosing sessions will include baseline measures and safety assessments; each session assesses criteria for safe home dosing and questionnaires to monitor acute effects and adverse events.

If a safe at-home dose is identified for all participants after completing all sessions, that dose will be considered the highest safe dose for future studies.